KMDA Kamada Ltd.

+0.08  (+1%)
Previous Close 5.94
Open 6.01
Price To Book 2.16
Market Cap 242410513
Shares 40,267,527
Volume 101,948
Short Ratio
Av. Daily Volume 28,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
Prophylaxis of rabies disease
Top-line data released August 30, 2016. Primary endpoint met. Company noted April 23, 2018 safety concerns by FDA. Initiation of Phase 3 trial planned for 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)